Weight Loss

Eli Lilly And Co (NYSE:LLY) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The company released its topline data from the trial in April. At 40...

A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically widening the bilateral trade imbalance. This year alone, $36 billion worth of hormone ingredients—...

Scholar Rock (NASDAQ:SRRK) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss. Tirzepatide is an active ingredient in Eli Lilly And Co’s (NYSE:LLY)...

Eli Lilly And Co (NYSE:LLY) announced on Monday that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—would soon be available in single-dose vials for $499 per month through LillyDirect’s Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program. Healthcare...

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management. Amycretin is developed for subcutaneous and oral administration. The decision to advance subcutaneous and oral amycretin into phase 3 is based on...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...

Juvena Therapeutics, Inc. on Wednesday entered a global licensing and multi-target research collaboration with Eli Lilly And Co (NYSE:LLY). The two companies aim to develop and commercialize drug candidates that improve muscle health and body composition. Juvena will leverage JuvNET, an AI-enabled...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases...

Metsera, Inc. (NASDAQ:MTSR) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera’s fully-biased monthly GLP-1 receptor agonist candidate, MET-097i....

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC:RHHBY) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company’s...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss. Novo...

Hims & Hers Health, Inc. (NYSE:HIMS) on Tuesday agreed to acquire ZAVA, a European digital health platform. The deal terms were not disclosed. The acquisition consideration will be 100% cash, funded from the company’s balance sheet at closing. The acquisition is expected to close in the...

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:LLY) on Tuesday. Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic...

ReShape Lifesciences (NASDAQ:RSLS) stock is trending up on Tuesday. Here’s what investors need to know. The premier physician-led weight loss and metabolic health solutions company’s Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in...